Integer Holdings Corp ITGR
We take great care to ensure that the data presented and summarized in this overview for Integer Holdings Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITGR
View all-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct29.5MShares$2.05 Billion1.53% of portfolio
-
Black Rock Inc. New York, NY5.32MShares$370 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$269 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.41MShares$98 Million0.03% of portfolio
-
State Street Corp Boston, MA1.32MShares$92 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.26MShares$87.5 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA1.11MShares$76.9 Million0.02% of portfolio
-
Earnest Partners LLC Atlanta, GA1.09MShares$75.5 Million0.51% of portfolio
-
Viking Global Investors LP1.02MShares$71.2 Million0.3% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN914KShares$63.5 Million0.02% of portfolio
Latest Institutional Activity in ITGR
Top Purchases
Top Sells
About ITGR
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Insider Transactions at ITGR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2025
|
John A Harris EVP, Global Ops and Manufactur |
BUY
Open market or private purchase
|
Direct |
1,650
+21.38%
|
$115,500
$70.0 P/Share
|
|
Nov 11
2025
|
Tommy P Thomas VP, Corporate Controller |
SELL
Open market or private sale
|
Direct |
884
-19.73%
|
$61,880
$70.15 P/Share
|
|
Nov 07
2025
|
Diron Smith EVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,115
+12.65%
|
$74,705
$67.19 P/Share
|
|
Nov 06
2025
|
Cheryl C Capps Director |
BUY
Open market or private purchase
|
Direct |
1,600
+12.03%
|
$105,600
$66.7 P/Share
|
|
Oct 30
2025
|
Payman Khales President & CEO |
BUY
Open market or private purchase
|
Direct |
3,127
+12.03%
|
$200,128
$64.94 P/Share
|
|
Jul 10
2025
|
Michael J Coyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,355
+50.0%
|
-
|
|
Jun 11
2025
|
Joseph W Dziedzic President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,395
-22.63%
|
$1,607,400
$120.03 P/Share
|
|
Jun 11
2025
|
Joseph W Dziedzic President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,202
+37.95%
|
-
|
|
Jun 05
2025
|
Martin C Maxwell Director |
SELL
Open market or private sale
|
Direct |
8,720
-6.1%
|
$1,046,400
$120.49 P/Share
|
|
Jun 05
2025
|
Martin C Maxwell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,720
+12.32%
|
$427,280
$49.9 P/Share
|
|
Jun 04
2025
|
Donald J Spence Director |
SELL
Open market or private sale
|
Direct |
14,739
-43.97%
|
$1,768,680
$120.38 P/Share
|
|
Jun 04
2025
|
Donald J Spence Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,739
+30.54%
|
$280,041
$19.43 P/Share
|
|
May 21
2025
|
Jean M. Hobby Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,514
+28.52%
|
-
|
|
May 21
2025
|
Martin C Maxwell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,514
+6.39%
|
-
|
|
May 21
2025
|
Cheryl C Capps Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,514
+13.03%
|
-
|
|
May 21
2025
|
Sheila Antrum Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,514
+13.03%
|
-
|
|
May 21
2025
|
Filippo Passerini Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,514
+4.94%
|
-
|
|
May 15
2025
|
Jim Stephens President, CRM & Neuro |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-8.61%
|
$14,280
$119.07 P/Share
|
|
May 15
2025
|
Jim Stephens President, CRM & Neuro |
BUY
Exercise of conversion of derivative security
|
Direct |
491
+26.05%
|
-
|
|
May 08
2025
|
Diron Smith EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
706
-9.69%
|
$84,014
$119.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 132K shares |
|---|---|
| Exercise of conversion of derivative security | 219K shares |
| Open market or private purchase | 7.49K shares |
| Open market or private sale | 363K shares |
|---|---|
| Payment of exercise price or tax liability | 91.8K shares |
| Bona fide gift | 24K shares |